Philip G. Febbo

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

David A. Quigley, Ha X. Dang, Shuang G. Zhao et al. · Cell · 2018 · 748 citations · Full text

Medicine, Genetics, Molecular Genetics +16

Analysis of oncogenic signaling networks in glioblastoma identifies <i>ASPM</i> as a molecular target

Steve Horvath, B. Zhang, Marc Carlson et al. · Proceedings of the National Academy of Sciences · 2006 · 672 citations · Full text

Medicine, Cancer Biology, Oncology +17

Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer

Michael B. Atkins, Meredith M. Regan, David F. McDermott et al. · Clinical Cancer Research · 2005 · 401 citations · Full text

Medicine, Oncology, Pathology +16

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

Mary‐Ellen Taplin, Daniel J. George, Susan Halabi et al. · Urology · 2005 · 102 citations

Medicine, Oncology, Urology +14

Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by ¹⁸F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687

Evan Y. Yu, Fenghai Duan, Mark Muzi et al. · Journal of Nuclear Medicine · 2015 · 57 citations · Full text

Medicine, Nuclear Medicine, Radiology +17